Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Health Economics and Outcomes Research, US Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Leuk Lymphoma. 2021 Jun;62(6):1411-1421. doi: 10.1080/10428194.2020.1869959. Epub 2021 Jan 11.
To describe real-world treatment patterns and outcomes among adult patients with myelodysplastic syndromes (MDS) treated with hypomethylating agents (HMA), patients were identified in the SEER-Medicare database (01/2006-12/2016); 3,046 patients with MDS treated with HMA were included. An algorithm was developed to categorize patients into MDS risk groups: the majority of patients were classified as Higher-risk (70.9%), 8.0% as Intermediate-risk, and 21.1% as Unknown-risk. Overall, 77.4% of patients initiated azacitidine and 22.6% decitabine; they received an average of 5.1 index-HMA cycles, of which 90.9% were complete with a median cycle duration of 28 days. Median survival was 11.6, 18.4, and 19.1 months for the Higher-risk, Intermediate-risk, and Unknown-risk groups, respectively. Median time-to-AML transformation was 19.3 months for the Higher-risk group and 50.4 months for the Intermediate-risk group (not reached for Unknown-risk). Data highlight the unmet medical needs of patients with MDS treated with HMA, particularly for the Higher-risk MDS group.
为了描述接受低甲基化药物（HMA）治疗的成人骨髓增生异常综合征（MDS）患者的真实世界治疗模式和结局，我们在 SEER-Medicare 数据库（2006 年 1 月至 2016 年 12 月）中确定了这些患者；共纳入了 3046 例接受 HMA 治疗的 MDS 患者。开发了一种算法将患者分为 MDS 风险组：大多数患者被归类为高危（70.9%），8.0%为中危，21.1%为未知风险。总体而言，77.4%的患者起始阿扎胞苷治疗，22.6%的患者起始地西他滨治疗；他们接受了平均 5.1 个 HMA 治疗周期，其中 90.9%的周期是完整的，中位周期持续时间为 28 天。高危、中危和未知风险组的中位总生存期分别为 11.6、18.4 和 19.1 个月。高危组的 AML 转化中位时间为 19.3 个月，中危组为 50.4 个月（未知风险组未达到）。数据突出了接受 HMA 治疗的 MDS 患者未满足的医疗需求，特别是高危 MDS 组。
